Zydus Cadila to seek emergency use authorisation for COVID-19 vaccine in India

Zydus Cadila may soon seek emergency use authorization for its vaccine from the Drug Controller General of India for children in the age group of 12-18.
Reports suggest that sources in the government and the company confirmed that the Ahmedabad-based firm may seek an emergency use authorization from the drug regulator in around a week.

If approved, this would be the first DNA-plasmid vaccine in the world. 
“The data analysis from the phase 3 trials is almost ready. The company may soon seek EUA for its vaccine,” a government official was quoted as saying.
According to the report, ZyCov-D, developed by Ahmedabad-based Zydus-Cadila, uses plasmid DNA (in contrast to mRNA as used by Pfizer-BioNTech and Moderna) to instruct human cells to make SARS-CoV-2 antigen eliciting an immune response. 
Therefore, it can be stored between 2-8 degrees Celsius, whereas the Pfizer-BioNTech vaccine requires cold-chain maintenance of up to -70 degrees Celsius, or at least -15 to -25 degrees Celsius. It is expected that the vaccine can be more easily “tweaked” than mRNA vaccines for use against variants.

Editor JK News Updates

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

All Centrally Protected ASI Monuments To Reopen From June 16

Mon Jun 14 , 2021
The Taj Mahal and other centrally protected monuments closed for around two months due to the Covid pandemic will be reopened on June 16, an ASI official said.Visitors will be able to book entry tickets online and no offline booking facility will be available, the Archaeological Survey of India (ASI) […]
%d bloggers like this: